Subconjunctival Versus Direct Mitomycin C in Trabeculectomy

Status Completed

Clinical Trial Summary

Trabeculectomy is routinely used as a surgical treatment for open angle glaucoma. Success of trabeculectomy is greatly augmented by the use of antimetabolites to inhibit wound healing, specifically Mitomycin C (MMC). MMC can be applied to the eye at various sites, concentrations and times. This study aims to compare the two application routes that are commonly employed: subconjunctival pre-operative injection and intraoperative direct scleral application in terms of IOP lowering effect, bleb appearance and complications.

Clinical Trial Description

Trabeculectomy is widely used as a surgical treatment of uncontrolled open glaucoma. Success of trabeculectomy at halting or slowing glaucoma progression primarily relies on the extent of conjunctival and sclera wound healing. The success rates of trabeculectomy increased dramatically with the introduction of anti-metabolites. For more than two decades mitomycin-c (MMC), a chemotherapeutic agent capable of decreasing fibroblast activity and modulating wound healing at the bleb, has been used with trabeculectomy. The complications of MMC are well known and several studies have described various methods of application based on exposure time, dose and surface area. Numerous retrospective and prospective studies have compared the efficacy of MMC applied beneath the conjunctival flap with soaked sponges versus intrascleral application. In 2008, Lee et al. first described an alternative route of application: subconjunctival injection of MMC directly into the intra-Tenon area. Seventy-six eyes with primary and secondary open angle glaucoma underwent trabeculectomy with this approach and were followed for one year post-operatively. Eighty-six percent of eyes achieved an IOP <21 mm Hg and 57% an IOP<14 mm Hg at one year without adjunctive drops. Transient complications included hyphema, bleb leak and choroidal detachment. The advantages of injected MMC are primarily in controlling the exact dosage and area of application and reduced surgical time. Lim et al. retrospectively reviewed the outcomes of trabeculectomy in 57 eyes using sponge application directly to the sclera versus intra-tenon injection. IOP was significantly lower in the injection group at 1 month, 1, 2, and 3 years. Trabeculectomy success (IOP<21mm Hg or IOP >20% below baseline without medications or additional surgery) was greater in the injection group at 3 years. The sponge group experienced more encapsulated blebs but complication rates were similar in both groups. To date, there have been no prospective studies comparing the IOP-lowering efficacy and safety of intra-tenon injection versus direct scleral application of MMC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04352660
Study type	Interventional
Source	University of California, San Diego
Contact
Status	Completed
Phase	Phase 4
Start date	May 23, 2016
Completion date	April 14, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03284853` - Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension	Phase 3
Terminated	`NCT03611530` - CoQun Study - (COQUN): a Study to Evaluate the Effects of CoQun in Patients Affected by Open-angle Glaucoma	N/A
Not yet recruiting	`NCT06441643` - Next Generation Rocklatan	Phase 2
Not yet recruiting	`NCT02868502` - Different Glaucoma Treatments Effect on Intraocular Pressure Fluctuation With Postural Change in Eyes With Open-angle Glaucoma	N/A
Completed	`NCT02628223` - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma	N/A
Completed	`NCT02272569` - STARflo European Safety and Efficacy Study	N/A
Completed	`NCT01936389` - A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma	Phase 2
Completed	`NCT00941525` - Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure	Phase 4
Completed	`NCT00539526` - Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues	Phase 4
Completed	`NCT00121147` - Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan	N/A
Active, not recruiting	`NCT05035394` - Swedish Microinvasive Glaucoma Surgery Study (SMIGS)	N/A
Completed	`NCT03450629` - Evaluation of Safety and Efficacy of PDP-716	Phase 3
Active, not recruiting	`NCT06061718` - Travoprost Intraocular Implant in Conjunction With Cataract Surgery	Phase 3
Recruiting	`NCT05241938` - PSLT Compared to Prostaglandin Analogue Eye Drops	N/A
Completed	`NCT01342406` - Effects of Selective Laser Trabeculoplasty on Aqueous Humor Dynamics
Completed	`NCT02250612` - SYL040012, Treatment for Open Angle Glaucoma	Phase 2
Completed	`NCT01937312` - Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue	Phase 4
Completed	`NCT01937299` - Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®	Phase 4
Terminated	`NCT01983579` - TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection	Phase 4
Completed	`NCT01229982` - A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma	Phase 2